SCHEMBL4771519

SCHEMBL4771519

NC(=O)C(Nc1cc(-c2cccnc2)nc(-c2ccccn2)n1)C(C(N)=O)c1ccc2ccccc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.40
SIRT2 Q8IXJ6 3/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TP53 P04637 1/20 0.38
PKM P14618 1/20 0.38
TSHR P16473 1/20 0.38
CYP2C9 P11712 3/20 0.38
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ATR Q13535 1/20 0.37
F2 P00734 2/20 0.37
F12 P00748 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ABL1 P00519 1/20 0.36
PDGFRB P09619 1/20 0.36
BCR P11274 1/20 0.36
PDGFRA P16234 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4766379 0.79 CYP2A6 (0.46) CYP2A6NPC1RAB9ASMN1; SMN2TP53
SCHEMBL4766345 0.79 CYP2A6 (0.46) CYP2A6NPC1RAB9ASMN1; SMN2TP53
SCHEMBL4771528 0.79 RAB9A (0.46) SIRT2NPC1RAB9ASMN1; SMN2TP53
SCHEMBL4771872 0.75 CYP2A6 (0.45) CYP2A6NPC1RAB9ASMN1; SMN2TP53
SCHEMBL3962124 0.71 CYP2A6 (0.46) CYP2A6NPC1RAB9ASMN1; SMN2TP53
SCHEMBL4774839 0.71 DYRK1A (0.51) CYP2A6NPC1RAB9ASMN1; SMN2TP53
SCHEMBL4771962 0.71 HDAC1 (0.44) CYP2A6CYP2C9KDM4ESCN5A
SCHEMBL4771979 0.71 HDAC1 (0.44) CYP2A6CYP2C9KDM4ESCN5A
SCHEMBL4776020 0.71 CDK4 (0.49) SMN1; SMN2MEN1KMT2AHTTSCN9A
SCHEMBL4773464 0.70 KDM1A (0.42) CYP2A6NPC1RAB9ASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed